Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group.

Authors

Katherine E. Warren, National Cancer Institute, Bethesda, MD
Tina Y. Poussaint, Children's Hospital, Boston, MA
Gilbert Vezina, George Washington UniversityFollow
Darren Hargrave, Great Ormond Street Hospital for Children
Roger J. Packer, George Washington UniversityFollow
Stewart Goldman, Lurie Children's Hospital of Chicago
Patrick Y. Wen, Dana-Farber Cancer Institute, Boston, MA
Ian F. Pollack, University of Pittsburgh
David Zurakowski, Harvard Medical School
Larry E. Kun, St. Jude Children's Research Hospital, Memphis, TN
Michael D. Prados, University of California - San Francisco
Stefan D. Rutkowski, University Medical Center, Hamburg-Eppendorf, Germany
Mark W. Kieran, Dana Farber Cancer Institute, Boston, MA

Document Type

Journal Article

Publication Date

9-2013

Journal

Pediatric Blood and Cancer

Volume

Volume 60, Issue 9

Inclusive Pages

1397-1401

APA Citation

Warren, K. E., Poussaint, T. Y., Vezina, G., Hargrave, D., Packer, R. J., Goldman, S., . . . Kieran, M. W. (2013). Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatric Blood and Cancer, 60(9), 1397-1401.

Peer Reviewed

1